The US Food and Drug Administration’s public comment period on regulating medical devices built on generative AI closed on 19 October. The agency’s paper, Considerations for the Regulation of Generative AI-Enabled Medical Devices, published in August under docket FDA-2026-N-7874, is a discussion paper rather than draft or final guidance: it asks targeted questions to inform future policy.
It lays out a possible two-axis framework for assessing risk, with premarket evaluation and postmarket monitoring scaled to that risk.
The American Hospital Association filed comments on the closing day. It asked the FDA to align premarket clearance with evaluation and monitoring after deployment under a total product lifecycle approach, to clarify that generative AI clinical decision support and administrative tools are not subject to FDA oversight, and to make developers primarily responsible for monitoring.
Why it matters: this is the FDA’s first structured attempt to define oversight for medical devices that run on large language models. Nothing in it is binding yet, and the hospital group’s positions are its own requests, not FDA policy.
Sources: The ASCO Post; American Hospital Association letter to the FDA, 19 Oct 2026.